Does This Move Make Merck Stock a Buy?

Merck is proactively addressing the impending patent cliff for its top-selling cancer drug, Keytruda, through a multi-pronged strategy. This includes significant acquisitions, such as the recent $10 billion purchase of Verona Pharma for its promising COPD treatment Ohtuvayre (estimated $4 billion peak sales), and prior deals like Acceleron Pharma ($11.5 billion) for Winrevair (estimated $3 billion peak sales). Concurrently, Merck is developing an internally-developed subcutaneous version of Keytruda, which recently demonstrated noninferiority in Phase 3 trials, aiming to mitigate revenue loss from future biosimilar competition. Despite the substantial revenue gap to fill from Keytruda's $29.5 billion in sales, Merck's deep pipeline, strategic diversification efforts, and attractive valuation (9.3x forward earnings vs. sector 16.2x) position the company for sustained performance post-Keytruda.

Analysis

Merck is executing a multi-faceted strategy to address the significant revenue risk posed by the upcoming patent cliff for its leading cancer drug, Keytruda, which generated $29.5 billion in sales last year. A core component of this strategy is aggressive M&A, exemplified by the recent $10 billion cash acquisition of Verona Pharma to gain its COPD treatment Ohtuvayre, which has estimated peak sales potential of $4 billion. This follows previous large deals, including the $11.5 billion purchase of Acceleron Pharma for its therapy Winrevair, projected to reach $3 billion in peak sales. While these acquisitions provide a combined $7 billion in potential revenue, a substantial gap remains. To further bridge this, Merck is advancing its internal pipeline, notably with a subcutaneous (SC) version of Keytruda that successfully demonstrated non-inferiority in a Phase 3 trial, aiming to retain market share post-patent expiry. The company's pipeline contains over 80 programs in mid-to-late-stage development, underscoring its long-term growth potential. Despite the overhang from the patent cliff, Merck's valuation appears discounted, trading at 9.3 times forward earnings compared to the healthcare sector average of 16.2, complemented by a strong dividend profile featuring a forward yield of approximately 4%.

Key Decisions for Investors

• Long-term investors may find Merck's current valuation at 9.3 times forward earnings, well below the sector average of 16.2, an attractive entry point given its proactive strategy to mitigate the upcoming Keytruda patent cliff.
• Investors should closely monitor the commercial launch performance of newly acquired assets Ohtuvayre and Winrevair, as their ability to meet or exceed peak sales estimates is critical for closing the projected $29.5 billion revenue gap.
• Key catalysts to watch include clinical trial data and regulatory milestones from the broader pipeline, particularly for candidates like MK-7240 from the Prometheus acquisition and the market adoption of the new subcutaneous Keytruda formulation.
• For income-oriented portfolios, the stock's approximate 4% dividend yield is compelling, but this must be weighed against the significant execution risk associated with replacing Keytruda's revenue and the stock's recent market underperformance.